Trial
NCT06337162
Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Incyte Corporation
Condition
Hepatocellular Carcinoma
Intervention
INCB099280
Why stopped
Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280) studies. This decision was made based on an internal review and reprioritization of the existing pipeline.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-09